Literature DB >> 28331987

Hypertension up to date: SPRINT to SPYRAL.

Saarraaken Kulenthiran1, Sebastian Ewen2, Michael Böhm2, Felix Mahfoud2.   

Abstract

Hypertension is the most common chronic cardiovascular condition with increasing prevalence all over the world. Treatment of patients at risk requires a multimodal therapeutic concept to adjust blood pressure, including systematic identification of secondary causes of hypertension or pseudo-resistance, lifestyle modification, polypharmacy, and as well as accompanying risk factors and comorbidities. The present review discusses recent studies on patients with increased cardiovascular risk potentially influencing future treatment strategies. It covers blood pressure targets in patients at risk (SPRINT), novel treatment options such as angiotensin receptor neprilysin inhibitors, discusses the treatment of patients with impaired glucose tolerance, and appreciates novelties in controlling therapy-resistant hypertension by fourth-line pharmacotherapies (PATHWAY), as well as new interventional approaches.

Entities:  

Keywords:  Angiotensin receptor neprilysin inhibitor; Glucose intolerance; Hypertension; Renal denervation; Resistant hypertension; SPRINT

Mesh:

Substances:

Year:  2017        PMID: 28331987     DOI: 10.1007/s00392-017-1095-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  48 in total

1.  Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation.

Authors:  Felix Mahfoud; Stefan Tunev; Sebastian Ewen; Bodo Cremers; Jennifer Ruwart; Daniel Schulz-Jander; Dominik Linz; Justin Davies; David E Kandzari; Robert Whitbourn; Michael Böhm; Robert J Melder
Journal:  J Am Coll Cardiol       Date:  2015-10-20       Impact factor: 24.094

Review 2.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney.

Authors:  Gerald F DiBona
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09       Impact factor: 3.619

3.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design.

Authors:  Felix Mahfoud; Michael Böhm; Michel Azizi; Atul Pathak; Isabelle Durand Zaleski; Sebastian Ewen; Kostantinos Tsioufis; Bert Andersson; Peter J Blankestijn; Michel Burnier; Gilles Chatellier; Sameer Gafoor; Guido Grassi; Michael Joner; Sverre E Kjeldsen; Thomas Felix Lüscher; Melvin D Lobo; Chaim Lotan; Gianfranco Parati; Josep Redon; Luis Ruilope; Isabella Sudano; Christian Ukena; Evert van Leeuwen; Massimo Volpe; Stephan Windecker; Adam Witkowski; William Wijns; Thomas Zeller; Roland E Schmieder
Journal:  Eur Heart J       Date:  2015-05-18       Impact factor: 29.983

4.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Authors:  Emmanuelle Vidal-Petiot; Ian Ford; Nicola Greenlaw; Roberto Ferrari; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Luigi Tavazzi; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Lancet       Date:  2016-08-30       Impact factor: 79.321

5.  Effects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs.

Authors:  Enrico Mossello; Mariachiara Pieraccioli; Nicola Nesti; Matteo Bulgaresi; Chiara Lorenzi; Veronica Caleri; Elisabetta Tonon; M Chiara Cavallini; Caterina Baroncini; Mauro Di Bari; Samuele Baldasseroni; Claudia Cantini; Carlo A Biagini; Niccolò Marchionni; Andrea Ungar
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

6.  First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

Authors:  Michael Böhm; Felix Mahfoud; Christian Ukena; Uta C Hoppe; Krzysztof Narkiewicz; Manuela Negoita; Luis Ruilope; Markus P Schlaich; Roland E Schmieder; Robert Whitbourn; Bryan Williams; Uwe Zeymer; Andreas Zirlik; Giuseppe Mancia
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

7.  Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension.

Authors:  Janine Pöss; Sebastian Ewen; Roland E Schmieder; Sonja Muhler; Oliver Vonend; Christian Ott; Dominik Linz; Jürgen Geisel; Lars C Rump; Markus Schlaich; Michael Böhm; Felix Mahfoud
Journal:  Clin Res Cardiol       Date:  2015-02-26       Impact factor: 5.460

8.  Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

Authors:  John B Kostis; Milton Packer; Henry R Black; Roland Schmieder; David Henry; Elliott Levy
Journal:  Am J Hypertens       Date:  2004-02       Impact factor: 2.689

9.  Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.

Authors:  Christina S Oxlund; Jan E Henriksen; Lise Tarnow; Karoline Schousboe; Jeppe Gram; Ib A Jacobsen
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

10.  Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Authors:  Morris J Brown; Bryan Williams; Steve V Morant; David J Webb; Mark J Caulfield; J Kennedy Cruickshank; Ian Ford; Gordon McInnes; Peter Sever; Jackie Salsbury; Isla S Mackenzie; Sandosh Padmanabhan; Thomas M MacDonald
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-18       Impact factor: 32.069

View more
  13 in total

1.  Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension.

Authors:  Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach
Journal:  Clin Res Cardiol       Date:  2019-04-06       Impact factor: 5.460

2.  Patient preference for therapies in hypertension: a cross-sectional survey of German patients.

Authors:  Roland E Schmieder; Karin Högerl; Susanne Jung; Peter Bramlage; Roland Veelken; Christian Ott
Journal:  Clin Res Cardiol       Date:  2019-04-02       Impact factor: 5.460

3.  Flow-mediated dilation, nitroglycerin-mediated dilation and their ratio predict successful renal denervation in mild resistant hypertension.

Authors:  Martin Steinmetz; Dominik Nelles; Jutta Weisser-Thomas; Christian Schaefer; Georg Nickenig; Nikos Werner
Journal:  Clin Res Cardiol       Date:  2018-04-11       Impact factor: 5.460

4.  Pregnancy outcome after first trimester use of angiotensin AT1 receptor blockers: an observational cohort study.

Authors:  Maria Hoeltzenbein; Tatjana Tissen-Diabaté; Anne-Katrin Fietz; Sandra Zinke; Angela Kayser; Reinhard Meister; Corinna Weber-Schoendorfer; Christof Schaefer
Journal:  Clin Res Cardiol       Date:  2018-03-24       Impact factor: 5.460

5.  [Blood pressure targets in patients with diabetes mellitus : What are optimum values?]

Authors:  J Dederer; Y Bewarder; F Mahfoud; M Böhm
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

6.  Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.

Authors:  Manuel Wallbach; Ellen Born; Deborah Kämpfer; Stephan Lüders; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Clin Res Cardiol       Date:  2019-08-06       Impact factor: 5.460

7.  Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension.

Authors:  Lucas Lauder; Sebastian Ewen; Abraham Rami Tzafriri; Elazer Reuven Edelman; Thomas Felix Lüscher; Peter J Blankenstijn; Oliver Dörr; Markus Schlaich; Faisal Sharif; Michiel Voskuil; Thomas Zeller; Christian Ukena; Bruno Scheller; Michael Böhm; Felix Mahfoud
Journal:  EuroIntervention       Date:  2018-05-20       Impact factor: 6.534

8.  The Effects of Intensive Blood Pressure Control on Cardiovascular Outcomes Based on 10-Year ASCVD Risk Score: An Analysis of a Clinical Trial.

Authors:  Alireza Alborzi; Armin Attar; Mehrab Sayadi; Fatemeh Nouri
Journal:  Cardiol Res Pract       Date:  2021-05-11       Impact factor: 1.866

9.  Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial.

Authors:  Lukas Stoiber; Felix Mahfoud; Seyedeh Mahsa Zamani; Tomas Lapinskas; Michael Böhm; Sebastian Ewen; Saarraaken Kulenthiran; Markus P Schlaich; Murray D Esler; Tommy Hammer; Knut Haakon Stensæth; Burkert Pieske; Stephan Dreysse; Eckart Fleck; Titus Kühne; Marcus Kelm; Philipp Stawowy; Sebastian Kelle
Journal:  Clin Res Cardiol       Date:  2018-03-08       Impact factor: 5.460

10.  Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Ling Zhang; Xiuting Sun; Lizhen Liao; Shaozhao Zhang; Huimin Zhou; Xiangbin Zhong; Xiaodong Zhuang; Xinxue Liao
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-10-31       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.